CV vs LNTH vs NNOX Stock Comparison

CapsoVision, Lantheus Holdings and Nano-X Imaging Prices as of Oct 28, 2026 Peers: Industry group
CV CapsoVision, Inc
$7.06 +2.0% 1M +50.5% 1Y
Market cap
$353.23M
P/E
–
Revenue (TTM)
$14.41M
Div. yield
–
Diagnostic Equipment Healthcare
LNTH Lantheus Holdings, Inc.
$100.10 +0.4% 1M +74.6% 1Y
Market cap
$6.53B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
8 wins
NNOX Nano-X Imaging Ltd.
$0.32 -49.2% 1M -91.8% 1Y
Market cap
$22.27M
P/E
–
Revenue (TTM)
$15.63M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

9 decided of 12

Lantheus Holdings leads on 8 of the 12 questions below (Lantheus Holdings 8, Nano-X Imaging 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCVLNTHNNOXLeader
Larger companyMarket capitalisation $353.23M $6.53B $22.27M LNTH
Cheaper on earningsLower P/E, profitable companies only -12.9x 23.7x -0.2x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 17.4x — –
Faster revenue growthRevenue growth, trailing twelve months +14.6% +2.3% +31.5% NNOX
More profitableNet margin, trailing twelve months -190.2% 17.7% -747.2% LNTH
Better return on capitalReturn on invested capital — 12.5% -116.9% LNTH
Less leveragedLower net debt / EBITDA — -0.1x 0.3x LNTH
Higher dividend yieldTrailing dividend yield 0.00% — — –
Better 1-year returnPrice return, last 12 months +50.5% +74.6% -91.8% LNTH
Better 5-year returnAnnualised price return, 5 years — +33.8%/yr -57.4%/yr LNTH
Less volatileAnnualised volatility, 1 year 96.0% 32.2% 105.8% LNTH
Higher overall scoreMean of the five percentile scores vs peers 37/100 80/100 36/100 LNTH

Percentile Scorecard

CVLNTHNNOX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCVLNTHNNOX
Valuation 6 #214 of 227 81 #44 of 227 52 #110 of 227
Growth 44 #124 of 219 62 #83 of 219 10 #197 of 219
Profitability 23 #158 of 205 94 #13 of 205 10 #185 of 205
Financial Health 75 #59 of 237 70 #73 of 237 70 #71 of 237
Shareholder Returns – 93 #11 of 135 –
Overall 37 80 36
  • CV ranked among 247 companies in Medical Devices and Diagnostics
  • LNTH ranked among 247 companies in Medical Devices and Diagnostics
  • NNOX ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCVLNTHNNOXSPY
1 month +2.0%+0.4%-49.2% +0.9%
3 months +6.5%+0.1%-63.6% +5.9%
6 months +10.3%+23.3%-81.3% +8.5%
Year to date -34.0%+50.4%-88.6% +13.3%
1 year +50.5%+74.6%-91.8% +12.4%
3 years —+49.8%-93.6% +88.1%
3 years, per year —+14.4%-60.1% +23.5%
5 years —+328.0%-98.6% +68.2%
5 years, per year —+33.8%-57.4% +11.0%
10 years —+1,128.2%— +263.4%
10 years, per year —+28.5%— +13.8%

Risk

MeasureCVLNTHNNOXSPY
Volatility, 1Y 96.0%32.2%105.8% 12.7%
Downside volatility, 1Y 89.6%27.5%116.6% 12.7%
Beta vs S&P 500, 1Y 0.620.591.37 1.00
Return / volatility, 1Y 0.532.31-0.87 0.98
Max drawdown, 5Y -67.8%-59.5%-98.8% -25.4%
From 52-week high -51.0%-9.8%-93.0% -0.9%
52-week high $14.42$110.94$4.55 $779.14
52-week low $4.59$50.69$0.32 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCVLNTHNNOX
P/E now vs peer median -12.9xmedian 28.8x 23.7xmedian 28.8x -0.2xmedian 28.8x
P/S now vs peer median 24.5xmedian 3.0x 4.2xmedian 3.0x 1.4xmedian 3.0x
EV/EBITDA now vs peer median -12.8xmedian 17.4x 16.5xmedian 17.4x 0.1xmedian 17.4x
P/FCF now vs peer median —median 25.7x 16.8xmedian 25.7x -0.4xmedian 25.7x
P/B now vs peer median 26.8xmedian 2.4x 5.0xmedian 2.4x 0.3xmedian 2.4x
PEG now vs peer median —median 1.03 0.22median 1.03 -0.08median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCVLNTHNNOX
Revenue $14.41M $1.56B $15.63M
Gross profit $7.55M $936.02M -$52.76M
Operating income -$27.71M $302.34M -$119.69M
Net income -$27.42M $275.31M -$116.81M
Free cash flow – $387.83M -$52.09M
R&D $20.51M $173.09M $18.93M
EPS (diluted) $-0.55 $4.08 $-1.80
Cash & equivalents – $593.30M $31.02M
Total debt – $571.05M $3.00M
Shares (diluted) 49.94M 67.52M 64.79M
Enterprise value $353.23M $4.70B -$157.41M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCVLNTHNNOX
P/E -12.9x 23.7x -0.2x
P/FCF – 16.8x -0.4x
P/Operating cash flow – 15.8x -0.5x
P/S 24.5x 4.2x 1.4x
P/B 26.8x 5.0x 0.3x
P/Tangible book 26.8x 10.5x 0.4x
EV/EBITDA -12.8x 16.5x 0.1x
EV/EBIT -12.7x 21.5x 0.0x
EV/Revenue 24.5x 4.2x -0.4x
EV/FCF – 16.8x 0.1x
EV/Operating cash flow – 15.8x 0.1x
PEG (3Y EPS CAGR) – 0.22 -0.08

Growth

14 metrics
MetricCVLNTHNNOX
Revenue growth (1Y) 14.6% 2.3% 31.5%
Revenue CAGR (3Y) – 11.4% 17.7%
Gross profit growth (1Y) 11.1% -3.4% -340.0%
Gross profit CAGR (3Y) – 16.3% -101.8%
Operating income growth (1Y) -36.1% -30.9% -107.4%
Operating income CAGR (3Y) – 118.8% -5.0%
Net income growth (1Y) -34.9% 1.6% -109.9%
Net income CAGR (3Y) – 102.1% -4.9%
EPS growth (1Y) 93.8% 5.8% -90.0%
EPS CAGR (3Y) – 105.5% 2.3%
Operating cash flow growth (1Y) – -21.7% -21.9%
Operating cash flow CAGR (3Y) – 14.5% -2.7%
Free cash flow growth (1Y) – -10.1% -19.4%
Free cash flow CAGR (3Y) – 103.0% 1.3%

Profitability

14 metrics
MetricCVLNTHNNOX
Gross margin 52.4% 60.1% -337.5%
EBITDA margin -190.7% 25.4% -692.4%
Operating margin -192.3% 19.4% -765.6%
Pretax margin -190.1% 23.3% -758.5%
Net margin -190.2% 17.7% -747.2%
FCF margin – 24.9% -333.2%
Operating cash flow margin – 26.5% -298.7%
Return on equity -207.5% 21.8% -117.5%
Return on assets -149.3% 11.6% -98.6%
Return on invested capital – 12.5% -116.9%
Return on capital employed -209.8% 14.8% -114.2%
Asset turnover 0.8x 0.7x 0.1x
Cash conversion (OCF / net income) – 1.5x 0.4x
Stock comp / revenue – 5.0% 34.9%

Financial Health

11 metrics
MetricCVLNTHNNOX
Debt / assets – 23.6% 3.3%
Debt / equity – 0.4x 0.0x
Net debt / EBITDA – -0.1x 0.3x
Debt / FCF – 1.5x -0.1x
Liabilities / assets 29.1% 45.7% 20.5%
Equity / assets 70.9% 54.3% 79.5%
Interest coverage – 15.3x –
Current ratio 3.4x 3.1x 2.8x
Quick ratio – 2.8x 2.4x
Cash ratio – 1.8x 2.3x
Altman Z-score 23.03 5.46 -11.07

Shareholder Returns

7 metrics
MetricCVLNTHNNOX
Dividend yield – – –
Net buyback yield – 2.9% –
Shareholder yield 0.0% 2.9% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCVLNTHNNOX
Forward P/E – 17.4xFY2026 –
EPS, next fiscal year $-0.58FY2026 $5.76FY2026 $-1.31FY2026
EPS growth, next FY – -5.3%FY2026 –
EPS growth, the year after – +4.2% –
Revenue, next fiscal year $13.91MFY2026 $1.57BFY2026 $18.64MFY2026
Revenue growth, next FY +2.7%FY2026 +1.8%FY2026 +43.2%FY2026
Revenue growth, the year after +46.0% +12.7% +59.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCVLNTHNNOX
Held by institutions 10.2% 100.0% 14.9%
Institutions holding 50 465 102
Change in shares held, QoQ +27.6% +3.4% -46.0%
Institutions buying 36 248 55
Institutions selling 8 142 28
Buyers to sellers 4.50 1.75 1.96

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CVLNTHNNOX
CV 1.00 0.07 0.04
LNTH 0.07 1.00 0.05
NNOX 0.04 0.05 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CV, LNTH and NNOX?

Lantheus Holdings (LNTH) is the largest by market capitalisation: CapsoVision (CV) $353.23M, Lantheus Holdings (LNTH) $6.53B, Nano-X Imaging (NNOX) $22.27M.

Which company is growing faster?

Nano-X Imaging (NNOX) grew revenue fastest over the trailing twelve months: CapsoVision (CV) +14.6%, Lantheus Holdings (LNTH) +2.3%, Nano-X Imaging (NNOX) +31.5%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (CapsoVision (CV) -190.2%, Lantheus Holdings (LNTH) 17.7%, Nano-X Imaging (NNOX) -747.2%). On return on invested capital, Lantheus Holdings (LNTH) leads (Lantheus Holdings (LNTH) 12.5%, Nano-X Imaging (NNOX) -116.9%).

Which stock has performed better?

Over the past year Lantheus Holdings (LNTH) returned the most: CapsoVision (CV) +50.5%, Lantheus Holdings (LNTH) +74.6%, Nano-X Imaging (NNOX) -91.8%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Lantheus Holdings (LNTH) +33.8%/yr, Nano-X Imaging (NNOX) -57.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (CapsoVision (CV) 96.0%, Lantheus Holdings (LNTH) 32.2%, Nano-X Imaging (NNOX) 105.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CV, LNTH and NNOX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.